国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2010年
10期
1855-1857
,共3页
人参皂甙Rg3%糖尿病视网膜病变%血管内皮生长因子%肿瘤坏死因子-α
人參皂甙Rg3%糖尿病視網膜病變%血管內皮生長因子%腫瘤壞死因子-α
인삼조대Rg3%당뇨병시망막병변%혈관내피생장인자%종류배사인자-α
ginsenoside-Rg3%diabetic retinopathy%vascular endothelial growth factor%tumor necrosis factor-α
目的:通过观察人参皂甙Rg3对糖尿病视网膜病变大鼠视网膜组织血管内皮生长因子(VEGF)以及肿瘤坏死因子-α(TNF-α)表达的影响,探讨人参皂甙Rg3对糖尿病视网膜新生血管的影响.方法:建立糖尿病大鼠模型,60只雄性Wistar大鼠随机分为正常对照组、糖尿病对照组和人参皂甙Rg3治疗组(5mg/kg,0.2mg/mL),开始治疗8wk后检测VEGF和TNF-α的表达情况.结果:正常对照组、糖尿病对照组和人参皂甙Rg3治疗组大鼠视网膜VEGF和TNF-α表达水平差异有统计学意义(F=129.363和211.992,P均<0.01),其中糖尿病对照组与人参皂甙Rg3治疗组大鼠均较正常对照组VEGF和TNF-α表达水平上调(P均<0.01),但人参皂甙Rg3治疗组视网膜组织 VEGF和TNF-α较糖尿病组降低(P均<0.01).结论:人参皂甙Rg3可下调糖尿病性视网膜病变大鼠视网膜组织中VEGF和TNF-α的表达,干预糖尿病视网膜病变的发生、发展.
目的:通過觀察人參皂甙Rg3對糖尿病視網膜病變大鼠視網膜組織血管內皮生長因子(VEGF)以及腫瘤壞死因子-α(TNF-α)錶達的影響,探討人參皂甙Rg3對糖尿病視網膜新生血管的影響.方法:建立糖尿病大鼠模型,60隻雄性Wistar大鼠隨機分為正常對照組、糖尿病對照組和人參皂甙Rg3治療組(5mg/kg,0.2mg/mL),開始治療8wk後檢測VEGF和TNF-α的錶達情況.結果:正常對照組、糖尿病對照組和人參皂甙Rg3治療組大鼠視網膜VEGF和TNF-α錶達水平差異有統計學意義(F=129.363和211.992,P均<0.01),其中糖尿病對照組與人參皂甙Rg3治療組大鼠均較正常對照組VEGF和TNF-α錶達水平上調(P均<0.01),但人參皂甙Rg3治療組視網膜組織 VEGF和TNF-α較糖尿病組降低(P均<0.01).結論:人參皂甙Rg3可下調糖尿病性視網膜病變大鼠視網膜組織中VEGF和TNF-α的錶達,榦預糖尿病視網膜病變的髮生、髮展.
목적:통과관찰인삼조대Rg3대당뇨병시망막병변대서시망막조직혈관내피생장인자(VEGF)이급종류배사인자-α(TNF-α)표체적영향,탐토인삼조대Rg3대당뇨병시망막신생혈관적영향.방법:건립당뇨병대서모형,60지웅성Wistar대서수궤분위정상대조조、당뇨병대조조화인삼조대Rg3치료조(5mg/kg,0.2mg/mL),개시치료8wk후검측VEGF화TNF-α적표체정황.결과:정상대조조、당뇨병대조조화인삼조대Rg3치료조대서시망막VEGF화TNF-α표체수평차이유통계학의의(F=129.363화211.992,P균<0.01),기중당뇨병대조조여인삼조대Rg3치료조대서균교정상대조조VEGF화TNF-α표체수평상조(P균<0.01),단인삼조대Rg3치료조시망막조직 VEGF화TNF-α교당뇨병조강저(P균<0.01).결론:인삼조대Rg3가하조당뇨병성시망막병변대서시망막조직중VEGF화TNF-α적표체,간예당뇨병시망막병변적발생、발전.
AIM: To investigate the effect of ginsenoside-Rg3 on the expression of vascular endothelial growth factor (VEGF) and tumor necrosis factor-α (TNF-α) in retina with diabetic rats and its roles in preventing neovascularization in diabetes. METHODS: Sixty male Wistar rats were divided into 3 groups randomly: negative control group, diabetic control group and ginsenoside-Rg3 treatment group (5mg/kg, 0.2mg/mL) followed by establishing diabetic model. The expression of VEGF and TNF-α were measured after 8 weeks. RESULTS: There were significant differences among negative control group, diabetic control group and ginsenoside-Rg3 treatment group in the expression of VEGF and TNF-α (F=129.363, 211.992; all the P<0.01). VEGF and TNF-α expression were significantly higher in diabetic control group and ginsenoside-Rg3 treatment group than that in negative control group (P<0.01), with a significant reduction in ginsenoside-Rg3 treatment group than that in diabetic control group (P<0.01). CONCLUSION: Ginsenoside-Rg3 can down-regulate the expression of VEGF and TNF-α in retina, which may interfere in the development of diabetic retinopathy.
